It has been proposed the potential efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors on NAFLD and “metabolic associated fatty liver disease (MAFLD) as recently reported by Goya al. [36]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.